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EDITORIAL
Changing  the rules  of  engagement:  Perspective  of Zikap
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Those  of  you  that  have  been  in  the  medical  ﬁeld  for
some  years  might  recall  that  over  the  last  3  decades,
we  have  encountered  outbreaks  and  epidemics  caused
by  old  enemies  that  for  some  reason  reemerged.  These
‘‘upgraded’’  microorganisms  reappeared  because  of  genetic
re-engineering  and/or  human  error;  some  examples  include
(but  are  not  restricted  to)  AH1N1  inﬂuenza,  Ebola,  MERS,
measles,  cholera,  etc.  These  epidemiological  events  as  oth-
ers  cause  morbidity  in  high  risk  groups  that  in  most  cases
include  pregnancy  and  children.  But  in  the  last  50  years  no
infectious  agent  of  epidemic  proportions  has  been  directly
linked  to  birth  defects  and  fetal  death;  Thus  the  rules  of
engagement  change.
Zika  virus  (ZIKV)  is  not  new,  description  of  the  virus  dates
back  to  1952,  what  is  new  is  our  understanding  of  its  effects
and  the  widespread  dissemination.  There  is  now  robust  evi-
dence  of  its  causal  effect  on  fetal  deaths,  microcephaly,
in  utero  growth  restriction,  ventricular  calciﬁcations,  cen-
tral  nervous  system  abnormalities,  and  changes  in  amniotic
ﬂuid  volume  as  well  as  cerebral  and  umbilical  artery
ﬂow.  Furthermore,  association  between  ZIKV  infection  and
Guillain--Barre  syndrome  are  growing.1
The  rapid  spread  of  the  virus  is  another  key  factor.
Like  other  arbovirus,  ZIKV  uses  a  common  mosquito  (Aedes
spp.)  for  transmission  and  has  spread  exponentially  in  Aedes
endemic  regions.  Since  2007,  62  countries  and  territories
have  documented  cases,  33  of  those  are  from  the  region  of
the  Americas  since  2015.  More  than  1000  cases  of  micro-
cephaly  have  been  reported  from  8  countries  an  another
13  have  reported  an  increase  incidence  in  GBS  linked  to
ZIKV.2 Recent  knowledge  of  other  mechanisms  of  transmis-
sion  other  than  mosquito  bites  such  as  sexual  intercourse,3
blood  donations  and  persistence  of  RNA  in  body  ﬂuids4 brings
new  insight  to  the  understanding  of  physiopathology.
The  disease  is  fairly  mild  in  most  cases  and  has  an
extremely  low  mortality  rate  in  the  immunocompetent  non-
pregnant  adult;  with  symptomatic  treatment  the  recovery
rate  is  excellent.  The  caveat  is  that  this  is  completely  differ-
ent  in  the  pregnant  patient.  Approximately  80%  of  infected
patients  will  not  develop  symptoms  and  about  40--50%  of
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4regnant  woman  infected  with  ZIKV  will  do  so.5 To  that  the
iagnostic  capability  is  poor,  the  methods  exist  but  they  are
ot  readily  available  in  highly  prevalent  areas.  Detection
y  PCR  is  performed  in  reference  laboratory’s  but  samples
re  mainly  drawn  from  symptomatic  patients  and  since  the
urrent  PCR  assay  detects  viral  RNA,  it  only  will  be  positive
uring  the  period  of  viremia  (5--7  days),  which  may  be  rel-
tively  short  thus  underestimating  the  incidence.  Antibody
esting  has  to  be  conﬁrmed  by  elevation  of  titers  or  a  molec-
lar  method  and  there  is  the  problem  of  cross-reactivity
etween  ﬂaviviruses.  IgM-antibody  assays  cannot  reliably
istinguish  between  ZIKV  and  dengue  virus  (DENV)  infec-
ions.  Therefore,  an  IgM-positive  result  on  an  enzyme-linked
mmunosorbent  assay  for  DENV  or  Zika  IgM  should  be  consid-
red  indicative  of  a  recent  ﬂavivirus  infection.  The  same
s  true  for  patients  that  who  have  received  yellow  fever
r  Japanese  encephalitis  vaccine  or  have  previously  been
nfected  with  another  ﬂavivirus,  cross-reactive  antibodies
ay  make  it  difﬁcult  to  determine  which  ﬂavivirus  is  caus-
ng  the  current  illness.  But  let’s  idealize  that  these  methods
re  available  and  accessible. .  . What  do  we  tell  the  pregnant
atient  after  the  test  comes  back  positive?  Anything  we  can
ay  other  than  ‘‘everything  will  be  all  right’’  to  this  point  is
nsettling  for  a  mother  to  be,  and  unfortunately  we  cannot
ssure  a  good  outcome.
The  World  Health  Organization  recently  declared  ZIKV
 global  emergency,  this  gives  the  highest  priority  for  epi-
emiological  control  efforts;  among  other  things  it  opens
p  grants  for  research  and  expedites  approval  of  research
rotocols.  Treatment  for  these  types  of  viruses  such  as
ENV,  Chikungunya,  etc.  are  cumbersome  to  develop  more
ver  the  diseases  they  cause  is  self  limited.  Vector  con-
rol  measures  are  inconsistent,  especially  in  underdeveloped
ountries  and  are  subject  to  many  environmental,  social  and
ven  political  variables;  this  makes  vaccine  development
he  obvious  choice.  The  technological  tools  exist  and  make  a
accine  feasible,  although  animal  models  and  preclinical  tri-
ls  will  have  to  be  expedited.  A  major  advance  in  developing
he  counterattack  is  that  Brazil’s  Agência  Nacional  de  Vig-
lância  Sanitária,  the  U.S.  Food  and  Drug  Administration,  and
asson Doyma Me´xico S.A. This is an open access article under the
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he  European  Medicines  Agency  have  committed  to  prioriti-
ing  the  expedited  evaluation  of  Zika  products.  Also,  there
s  a  real-time  posting  of  preliminary  information  regulated
y  the  International  Committee  of  Medical  Journal  Editors
larifying  that  prepublication  dissemination  of  critical  infor-
ation  will  not  prejudice  later  journal  publication  related
o  ZIKV  or  future  public  health  emergencies  has  been  help-
ul  these  advances  are  unprecedented  and  will  surely  lead
o  vaccine  development.  Although  some  questions  start  to
ome  up,  after  the  preclinical  trials  who  will  be  the  ﬁrst  tar-
eted  population  to  receive  the  vaccine?  Nonpregnant  adult
omen?  Pregnant  patients  in  high  risk  areas?  These  questions
re  going  to  have  to  be  addressed  relatively  quickly.
Every  biological  species  try  to  preserve  their  young,  par-
nts  will  literally  give  their  lives  for  their  offspring  in  order
o  continue  the  species’  existence;  Humans  do  not  differ.  We
s  a  species,  have  done  extraordinary  things  to  preserve  our
ext  generations,  we  develop  vaccines,  medications,  pro-
rams  for  food  and  clean  water  access,  etc.  We  may  be
olerable  to  some  extent  to  other  illness,  but  not  those
hat  compromise  our  unborn  children  and  their  pregnant
others,  here  there  is  no  tolerance.  Many  questions  remain
nanswered  for  now,  but  what  is  clear  is  that  in  order  to
ontrol  and  prevent  the  spread  of  ZIKV  we  must  change  the
ay  we  commonly  think  for  this  old  fowl  is  not  a  common
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